Won Seog Kim
Research Subjects
Research Interests
Won Seog Kim has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Seok Jin Kim
Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
7 shared publications - Young Hyeh Ko
Samsung Medical Center, Department of Pathology Sungkyunkwan University School of Medicine Seoul Republic of Korea
6 shared publications - Kihyun Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Chaehwa Park
Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea
3 shared publications Joo Hyun Kim
Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea
3 shared publicationsSeok Jin Kim
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea
3 shared publications
Latest Publications
- Open Access
Changes in Cancer Care for Patients Aged 80 and Above: A Cohort Study from Samsung Comprehensive Cancer Center in South Korea
Background/Objectives: With an estimated 70% of new cancer diagnoses expected to be in older adults within the next decade, cancer care for this population has attracted increasing global attention. Additionally, older patients are less likely to receive optimal cancer treatments. Methods: This retrospective cohort study utilized data from the Samsung Medical Center Cancer Registry, which includes patients diagnosed with cancer between 2008 and 2022. A 15-year cohort analysis was conducted to examine trends and survival outcomes by cancer type and stage in patients aged 80 years and older. Results: Among 301,055 patients with cancer, 13,111 (4.4%) were aged 80 years or older at diagnosis. The proportion of patients in this age group increased from 2.4% in 2008 to 5.8% in 2022. The most prevalent cancers in patients aged ≥80 years were lung (18.9%), stomach (15.3%), and colorectal cancer (13.8%). Among individuals with localized or regional-stage disease, the 5-year survival rate was 49.66% in those aged ≥80 years compared to 81.46% in younger patients (HR = 1.41; 95% CI = 1.35, 1.46). For distant-stage disease, survival was lower, at 10.53% in patients aged ≥80 years versus 27.61% in those aged <80 (HR = 1.14; 95% CI = 1.10, 1.19). Among patients aged 80 years and older, 55% received anti-cancer treatment, with the proportion increasing from 54.5% in 2008 to 60.3% in 2021. This increase was particularly notable in individuals with distant-stage disease. Additionally, the proportion of clinical trial participants aged ≥80 years exhibited an upward trend. Patients in this age group who underwent treatment had significantly improved survival compared to those who did not, in both localized or regional disease (HR = 0.45; 95% CI = 0.42, 0.49) and distant disease (HR = 0.58; 95% CI = 0.53, 0.62). Conclusions: The findings from this cohort of the SMC Cancer Registry highlight key trends, including a rising number of patients aged ≥80 years and an increasing proportion receiving treatment, particularly after 2020, when more than 60% received therapy. Furthermore, survival benefits associated with treatment were comparable to those observed in younger patients across all cancer types.
Open AccessChanges in Cancer Care for Patients Aged 80 and Above: A Cohort Study from Samsung Comprehensive Cancer Center in South Korea
Background/Objectives: With an estimated 70% of new cancer diagnoses expected to be in older adults within the next decade, cancer care for this population has attracted increasing global attention. Additionally, older patients are less likely to receive optimal cancer treatments. Methods: This retrospective cohort study utilized data from the Samsung Medical Center Cancer Registry, which includes patients diagnosed with cancer between 2008 and 2022. A 15-year cohort analysis was conducted to examine trends and survival outcomes by cancer type and stage in patients aged 80 years and older. Results: Among 301,055 patients with cancer, 13,111 (4.4%) were aged 80 years or older at diagnosis. The proportion of patients in this age group increased from 2.4% in 2008 to 5.8% in 2022. The most prevalent cancers in patients aged ≥80 years were lung (18.9%), stomach (15.3%), and colorectal cancer (13.8%). Among individuals with localized or regional-stage disease, the 5-year survival rate was 49.66% in those aged ≥80 years compared to 81.46% in younger patients (HR = 1.41; 95% CI = 1.35, 1.46). For distant-stage disease, survival was lower, at 10.53% in patients aged ≥80 years versus 27.61% in those aged <80 (HR = 1.14; 95% CI = 1.10, 1.19). Among patients aged 80 years and older, 55% received anti-cancer treatment, with the proportion increasing from 54.5% in 2008 to 60.3% in 2021. This increase was particularly notable in individuals with distant-stage disease. Additionally, the proportion of clinical trial participants aged ≥80 years exhibited an upward trend. Patients in this age group who underwent treatment had significantly improved survival compared to those who did not, in both localized or regional disease (HR = 0.45; 95% CI = 0.42, 0.49) and distant disease (HR = 0.58; 95% CI = 0.53, 0.62). Conclusions: The findings from this cohort of the SMC Cancer Registry highlight key trends, including a rising number of patients aged ≥80 years and an increasing proportion receiving treatment, particularly after 2020, when more than 60% received therapy. Furthermore, survival benefits associated with treatment were comparable to those observed in younger patients across all cancer types.
- 15 April 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (6) , 1293-1302
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
Cell-free DNA (cfDNA) can be released from tumor cells during proliferation and apoptosis; thus, a fraction of the cfDNA in patients with cancer is tumor-derived. However, the prognostic value of cfDNA in aggressive non-Hodgkin lymphoma (NHL) has not been determined. Between March 2017 and April 2019, plasma cfDNA was obtained from 158 patients with aggressive NHL who were registered in a prospective Samsung Medical Center lymphoma cohort (diffuse large B cell lymphoma (DLBCL), n = 51; T cell lymphoma (TCL), n = 51; NK/T cell lymphoma (NKTCL), n = 56). The concentration of cfDNA was estimated in longitudinal samples collected from patients with NHL before and during various chemotherapy regimens. In pretreatment samples, the median cfDNA concentration of all patients with aggressive lymphoma was 13.7 ng/dl (range 1.7–1792), which was significantly higher than that of healthy volunteers (median 7.4 ng, range 3.7–14.4, p < 0.001), and advanced stages showed a higher cfDNA level than earlier stages. Multivariate analysis identified high cfDNA as an independent factor for event-free survival that predicted poor prognosis in DLBCL (hazard ratio [HR] = 5.33, 95% confidence interval [CI] = 1.72–16.52, p = 0.003) and TCL (HR = 2.82, 95% CI = 1.10–7.20, p = 0.030). NKTCL patients with a high level of cfDNA had worse overall survival (HR = 4.71, 95% CI = 1.09–20.35, p = 0.037) compared with those with a low level of cfDNA. In this study, our results suggest the usefulness of pretreatment cfDNA as a prognostic marker for patients with DLBCL, TCL, and NKTCL.
- 15 April 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (6) , 1293-1302
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
Cell-free DNA (cfDNA) can be released from tumor cells during proliferation and apoptosis; thus, a fraction of the cfDNA in patients with cancer is tumor-derived. However, the prognostic value of cfDNA in aggressive non-Hodgkin lymphoma (NHL) has not been determined. Between March 2017 and April 2019, plasma cfDNA was obtained from 158 patients with aggressive NHL who were registered in a prospective Samsung Medical Center lymphoma cohort (diffuse large B cell lymphoma (DLBCL), n = 51; T cell lymphoma (TCL), n = 51; NK/T cell lymphoma (NKTCL), n = 56). The concentration of cfDNA was estimated in longitudinal samples collected from patients with NHL before and during various chemotherapy regimens. In pretreatment samples, the median cfDNA concentration of all patients with aggressive lymphoma was 13.7 ng/dl (range 1.7–1792), which was significantly higher than that of healthy volunteers (median 7.4 ng, range 3.7–14.4, p < 0.001), and advanced stages showed a higher cfDNA level than earlier stages. Multivariate analysis identified high cfDNA as an independent factor for event-free survival that predicted poor prognosis in DLBCL (hazard ratio [HR] = 5.33, 95% confidence interval [CI] = 1.72–16.52, p = 0.003) and TCL (HR = 2.82, 95% CI = 1.10–7.20, p = 0.030). NKTCL patients with a high level of cfDNA had worse overall survival (HR = 4.71, 95% CI = 1.09–20.35, p = 0.037) compared with those with a low level of cfDNA. In this study, our results suggest the usefulness of pretreatment cfDNA as a prognostic marker for patients with DLBCL, TCL, and NKTCL.
- 18 February 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (9) , 2237-2246
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes
Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We designed a panel targeting 66 genes associated with NHLs and performed targeted deep sequencing to analyze plasma cfDNA from patients with various subtypes of NHLs. Genetic profiling in plasma cfDNA using the method resulted in 88.0% sensitivity and >99% specificity in detecting mutations present at a frequency greater than 20% in the tumor biopsies. Furthermore, the level of ctDNA significantly decreased and increased depending on designated clinical responses to therapy and disease progression. These results demonstrated that ctDNA sensitively indicated the presence of cancer and reliably correlated with tumor burden, suggesting potential utility of the method for patients with various subtypes of NHLs.
- 18 February 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (9) , 2237-2246
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes
Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We designed a panel targeting 66 genes associated with NHLs and performed targeted deep sequencing to analyze plasma cfDNA from patients with various subtypes of NHLs. Genetic profiling in plasma cfDNA using the method resulted in 88.0% sensitivity and >99% specificity in detecting mutations present at a frequency greater than 20% in the tumor biopsies. Furthermore, the level of ctDNA significantly decreased and increased depending on designated clinical responses to therapy and disease progression. These results demonstrated that ctDNA sensitively indicated the presence of cancer and reliably correlated with tumor burden, suggesting potential utility of the method for patients with various subtypes of NHLs.
- 11 October 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 98 (2) , 457-464
Validation of the Marginal Zone Lymphoma International Prognostic Index
The Marginal Zone Lymphoma International Prognostic Index (MALT-IPI) was recently developed for use in patients with mucosa-associated lymphoid tissue (MALT) lymphoma based on age, serum lactate dehydrogenase level, and Ann Arbor stage. In this study, we aimed to validate the MALT-IPI. A total of 455 MALT lymphoma patients were included in this study from between January 2005 and February 2017. Event-free survival (EFS), progression-free survival (PFS), cause-specific survival (CSS), and overall survival (OS) were the primary outcomes. Of the 455 patients, MALT-IPI low-, intermediate-, and high-risk groups included 309 (67.9%), 126 (27.7%), and 20 (4.4%) individuals, respectively. When comparing the low-risk group (L MALT-IPI) with the intermediate–high-risk group (I-H MALT-IPI), EFS, PFS, CSS, and OS were significantly different (p = 0.000, p = 0.000, p = 0.027, and p = 0.037). The International Prognostic Index and the Follicular Lymphoma International Prognostic Index failed to predict the prognosis of MALT lymphoma. Use of the MALT-IPI significantly differentiated L MALT-IPI from I-H MALT-IPI with respect to EFS, PFS, CSS, and OS. MALT-IPI is a valuable tool for the prediction of MALT lymphoma prognosis.
- 11 October 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 98 (2) , 457-464
Validation of the Marginal Zone Lymphoma International Prognostic Index
The Marginal Zone Lymphoma International Prognostic Index (MALT-IPI) was recently developed for use in patients with mucosa-associated lymphoid tissue (MALT) lymphoma based on age, serum lactate dehydrogenase level, and Ann Arbor stage. In this study, we aimed to validate the MALT-IPI. A total of 455 MALT lymphoma patients were included in this study from between January 2005 and February 2017. Event-free survival (EFS), progression-free survival (PFS), cause-specific survival (CSS), and overall survival (OS) were the primary outcomes. Of the 455 patients, MALT-IPI low-, intermediate-, and high-risk groups included 309 (67.9%), 126 (27.7%), and 20 (4.4%) individuals, respectively. When comparing the low-risk group (L MALT-IPI) with the intermediate–high-risk group (I-H MALT-IPI), EFS, PFS, CSS, and OS were significantly different (p = 0.000, p = 0.000, p = 0.027, and p = 0.037). The International Prognostic Index and the Follicular Lymphoma International Prognostic Index failed to predict the prognosis of MALT lymphoma. Use of the MALT-IPI significantly differentiated L MALT-IPI from I-H MALT-IPI with respect to EFS, PFS, CSS, and OS. MALT-IPI is a valuable tool for the prediction of MALT lymphoma prognosis.
- Open Access
- 1 August 2017
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 92 (4) , 415-418
Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab. (
- 1 August 2017
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 92 (4) , 415-418
Open AccessComplete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab. (
- 16 November 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (6) , 1406-1412
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1–5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27–74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1–26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).
- 16 November 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (6) , 1406-1412
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1–5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27–74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1–26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).
- 3 June 2015
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 5 (10) , 960-966
Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type
- 3 June 2015
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 5 (10) , 960-966
Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type
- 1 June 2015
- Vol. 35 (6) , 3333-40
Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.
The purpose of the present study was to compare microarray gene-expression profiling data between primary central nervous system (CNS) lymphoma and non-CNS lymphomas. We performed whole-genomic cDNA-mediated annealing, selection and ligation assay with 177 formalin-fixed paraffin-embedded tumor samples. We identified 20 differentially expressed genes out of which 5 were predominantly expressed in CNS DLBCL compared to non-CNS DLBCL (C16orf59, SLC16A9, HPDL, SPP1, and MAG). SLC16A9 may be involved in aerobic glycolysis of malignant tumors. The alteration in gene expression of SPP1 in primary CNS lymphoma is involved in biological activity, such as CNS tropism, B-cell migration, proliferation, and aggressive clinical behavior. MAG may be an important adhesion molecule that contributes to perineural cancer invasion. Genomic differences between CNS and non-CNS DLBCL exist and the most prominent genes are SPP1 and MAG. SPP1 may play a key role in CNS tropism of primary CNS lymphoma.
- 1 June 2015
- Vol. 35 (6) , 3333-40
Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.
The purpose of the present study was to compare microarray gene-expression profiling data between primary central nervous system (CNS) lymphoma and non-CNS lymphomas. We performed whole-genomic cDNA-mediated annealing, selection and ligation assay with 177 formalin-fixed paraffin-embedded tumor samples. We identified 20 differentially expressed genes out of which 5 were predominantly expressed in CNS DLBCL compared to non-CNS DLBCL (C16orf59, SLC16A9, HPDL, SPP1, and MAG). SLC16A9 may be involved in aerobic glycolysis of malignant tumors. The alteration in gene expression of SPP1 in primary CNS lymphoma is involved in biological activity, such as CNS tropism, B-cell migration, proliferation, and aggressive clinical behavior. MAG may be an important adhesion molecule that contributes to perineural cancer invasion. Genomic differences between CNS and non-CNS DLBCL exist and the most prominent genes are SPP1 and MAG. SPP1 may play a key role in CNS tropism of primary CNS lymphoma.
- 8 April 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (11) , 3052-3057
A subset of CD45+/CD19 − cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 − was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 − cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 − cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 − cells decreased (mean: 0.012%), and CD45+/CD19 − cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 − cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.
- 8 April 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (11) , 3052-3057
A subset of CD45+/CD19 − cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 − was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 − cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 − cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 − cells decreased (mean: 0.012%), and CD45+/CD19 − cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 − cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.